Publication at Faculty of Medicine in Pilsen |
2017
Abstract
Author presented as an overview of recent systemic theraputic modalities which should be given to patients with advanced and metastatic non small cell lung cancers. The emphasive contributions of imunohistochemistry nd genetics for indications of histology - oriented chemotherapy, targeted therapies with tyrozinkinase inhibiotrs of EGFR, ALK and ROS1 bearing tumours, as well as for indications of imune check point inhibitors.